Data Sheet

Product Name:	GSK-872
Cat. No.:	CS-7609
CAS No.:	1346546-69-7
Molecular Formula:	C19H17N3O2S2
Molecular Weight:	383.49
Target:	RIP kinase
Pathway:	Apoptosis
Solubility:	DMSO : ≥ 100 mg/mL (260.76 mM)



BIOLOGICAL ACTIVITY:

GSK-872 is a **RIPK3** inhibitor, which binds RIP3 kinase domain with an **IC_{50}** of 1.8 nM, and inhibits kinase activity with an **IC_{50}** of 1.3 nM. IC50 & Target: IC50: 1.3 nM (RIPK3)[1] **In Vitro:** GSK-872 (GSK'872; 0.01-3 μM; 24 hours) blocks TNF-induced necroptosis in human HT-29 cells in a concentration-dependent manner[1].

PROTOCOL (Extracted from published papers and Only for reference)

Cell Assay: [2]Cell viability is estimated by Trypan blue exclusion and MTT assay. Treatment of inhibitors [N-acetyl Cysteine (NAC), butylated hydroxyanisole (BHA), IM54, Bay11-7082, Z-VAD-FMK, caspase-8 inhibitor, GSK-872 (200 nM) and necrostatin-1 (Nec-1)] is given for 4 h before Deltamethrin (DLM) treatment[2].

References:

[1]. Mandal P, et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell. 2014 Nov 20;56(4):481-95.

[2]. Arora D, et al. Deltamethrin induced RIPK3-mediated caspase-independent non-apoptotic cell death in rat primary hepatocytes. Biochem Biophys Res Commun. 2016 Oct 14;479(2):217-223.

CAIndexNames:

4-Quinolinamine, N-5-benzothiazolyl-6-[(1-methylethyl)sulfonyl]-

SMILES:

O=S(C1=CC=C2N=CC=C(NC3=CC=C(SC=N4)C4=C3)C2=C1)(C(C)C)=O

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA